Rock Springs Capital Management LP Ultragenyx Pharmaceutical Inc. Transaction History

Rock Springs Capital Management LP

$2.94 Billion
Q3 2024

A detailed history of Rock Springs Capital Management LP transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Rock Springs Capital Management LP holds 1,978,272 shares of RARE stock, worth $94.2 Million. This represents 3.74% of its overall portfolio holdings.

Number of Shares

1,978,272

Previous 1,924,072 2.82%

Holding current value

$94.2 Million

Previous $79.1 Million 38.97%

% of portfolio

3.74%

Previous 2.45%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$40.21 - $59.36 $2.18 Million - $3.22 Million	54,200 Added 2.82%	1,978,272 $110 Million
Q2 2024 Aug 14, 2024	BUY	$37.42 - $51.61 $5.58 Million - $7.7 Million	149,134 Added 8.4%	1,924,072 $79.1 Million
Q1 2024 May 15, 2024	BUY	$43.02 - $53.69 $899,118 - $1.12 Million	20,900 Added 1.19%	1,774,938 $82.9 Million
Q4 2023 Feb 14, 2024	BUY	$31.73 - $49.19 $8.81 Million - $13.7 Million	277,597 Added 18.8%	1,754,038 $83.9 Million
Q3 2023 Nov 14, 2023	BUY	$34.92 - $46.66 $3.22 Million - $4.3 Million	92,172 Added 6.66%	1,476,441 $52.6 Million
Q2 2023 Aug 14, 2023	BUY	$37.35 - $52.15 $1.79 Million - $2.5 Million	47,868 Added 3.58%	1,384,269 $63.9 Million
Q1 2023 May 15, 2023	BUY	$36.99 - $48.71 $1.71 Million - $2.25 Million	46,122 Added 3.57%	1,336,401 $53.6 Million
Q4 2022 Feb 14, 2023	BUY	$33.72 - $46.33 $3.45 Million - $4.74 Million	102,287 Added 8.61%	1,290,279 $59.8 Million
Q3 2022 Nov 14, 2022	BUY	$39.96 - $66.14 $3.79 Million - $6.28 Million	94,962 Added 8.69%	1,187,992 $49.2 Million
Q2 2022 Aug 15, 2022	BUY	$45.8 - $85.4 $2.97 Million - $5.54 Million	64,921 Added 6.31%	1,093,030 $65.2 Million
Q1 2022 May 16, 2022	BUY	$62.2 - $84.4 $8.97 Million - $12.2 Million	144,188 Added 16.31%	1,028,109 $74.7 Million
Q4 2021 Feb 14, 2022	BUY	$73.71 - $87.86 $6.1 Million - $7.28 Million	82,812 Added 10.34%	883,921 $74.3 Million
Q3 2021 Nov 15, 2021	BUY	$77.92 - $102.4 $26.2 Million - $34.4 Million	336,109 Added 72.28%	801,109 $72.3 Million
Q2 2021 Aug 16, 2021	BUY	$92.19 - $115.71 $1.38 Million - $1.74 Million	15,000 Added 3.33%	465,000 $44.3 Million
Q1 2021 May 17, 2021	SELL	$106.9 - $167.73 $12.5 Million - $19.5 Million	-116,500 Reduced 20.56%	450,000 $51.2 Million
Q4 2020 Feb 16, 2021	SELL	$84.4 - $177.39 $872,780 - $1.83 Million	-10,341 Reduced 1.79%	566,500 $78.4 Million
Q3 2020 Nov 16, 2020	SELL	$72.98 - $90.0 $5.11 Million - $6.3 Million	-70,000 Reduced 10.82%	576,841 $47.4 Million
Q2 2020 Aug 14, 2020	SELL	$46.91 - $78.22 $4.74 Million - $7.9 Million	-100,959 Reduced 13.5%	646,841 $50.6 Million
Q1 2020 May 15, 2020	BUY	$33.8 - $62.9 $1.62 Million - $3.01 Million	47,800 Added 6.83%	747,800 $33.2 Million
Q4 2019 Feb 14, 2020	BUY	$36.08 - $45.83 $3.32 Million - $4.22 Million	92,000 Added 15.13%	700,000 $29.9 Million
Q3 2019 Nov 14, 2019	BUY	$42.5 - $63.11 $1.19 Million - $1.77 Million	28,000 Added 4.83%	608,000 $26 Million
Q1 2019 May 15, 2019	BUY	$39.87 - $69.36 $6.18 Million - $10.8 Million	155,000 Added 36.47%	580,000 $40.2 Million
Q4 2018 Feb 14, 2019	BUY	$38.89 - $77.3 $8.75 Million - $17.4 Million	225,000 Added 112.5%	425,000 $18.5 Million
Q2 2018 Aug 14, 2018	BUY	$48.54 - $85.31 $1.31 Million - $2.3 Million	27,000 Added 15.61%	200,000 $15.4 Million
Q1 2018 May 15, 2018	BUY	$44.33 - $58.52 $443,300 - $585,200	10,000 Added 6.13%	173,000 $8.82 Million
Q3 2017 Nov 14, 2017	BUY	$49.79 - $66.32 $8.12 Million - $10.8 Million	163,000	163,000 $8.68 Million

Others Institutions Holding RARE

# of Institutions

326

Shares Held

85.7M

Call Options Held

520K

Put Options Held

406K

View Full List

About Ultragenyx Pharmaceutical Inc.

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.33B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

More about RARE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rock Springs Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Rock Springs Capital Management LP with notifications on news.

Account

Rock Springs Capital Management LP Ultragenyx Pharmaceutical Inc. Transaction History